Month: July 2020

MARSEILLE, France, July 16, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the appointment of Dr. Joyson Karakunnel as Executive Vice President and Chief Medical Officer (CMO). Dr. Pierre Dodion, CMO since 2014, is retiring from this position.Dr. Karakunnel comes to the Company with deep experience in immuno-oncology, and a proven track record in drug development. As CMO, he will be responsible for advancing Innate’s clinical pipeline and will lead a global team focused on clinical strategy, patient safety, regulatory and medical affairs.Most recently, Dr. Karakunnel served as CMO and Senior Vice President at Tizona Therapeutics, where he led the development of the company’s biotherapeutics pipeline. Prior to Tizona, he held positions...

Idorsia inaugurates its US commercial operations, located in Radnor, PA, United StatesIdorsia Pharmaceuticals US Inc. to be led by 20-year biopharmaceutical veteran Patricia TorrFor more information about Idorsia Pharmaceutical US Inc. please visit www.idorsia.usAllschwil, Switzerland – July 16, 2020Idorsia Ltd (SIX: IDIA) today announced its strategic expansion in the United States by establishing commercial operations. Located in Radnor, PA – a Philadelphia suburb known for its strong healthcare and pharmaceutical environment – Idorsia Pharmaceuticals US Inc. has been established to further develop and embed Idorsia’s budding global commercial organization and realize the value of its innovations by ensuring patients can benefit from the company’s pioneering therapies.  Idorsia US will be led by Patricia “Patty” Torr, President and...

•      Idorsia weiht ihre amerikanische Verkaufsorganisation in Radnor, Pennsylvania, USA, ein•      Idorsia Pharmaceuticals US Inc. wird von Patricia Torr, einer Führungskraft mit über 20-jähriger Erfahrung in der biopharmazeutischen Industrie geleitet•      Weitere Informationen über Idorsia Pharmaceuticals US Inc. finden sich auf www.idorsia.usAllschwil, Schweiz – 16. Juli 2020Idorsia Ltd (SIX: IDIA) gab heute die Gründung ihrer US-Verkaufsorganisation und damit ihre strategische Expansion in die Vereinigten Staaten bekannt. Idorsia Pharmaceuticals US Inc. mit Sitz in Radnor, PA – einem Vorort von Philadelphia, der für die starke Präsenz von Einrichtungen und Unternehmen aus dem Gesundheits- und Pharmabereich bekannt ist – wurde mit dem Ziel gegründet, die aufstrebende globale kommerzielle Organisation des Unternehmens weiterzuentwickeln...

Pierre Dodion, MD retires as Chief Medical OfficerInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the appointment of Dr. Joyson Karakunnel as Executive Vice President and Chief Medical Officer (CMO). Dr. Pierre Dodion, CMO since 2014, is retiring from this position.Dr. Karakunnel comes to the Company with deep experience in immuno-oncology, and a proven track record in drug development. As CMO, he will be responsible for advancing Innate’s clinical pipeline and will lead a global team focused on clinical strategy, patient safety, regulatory and medical affairs.Most recently, Dr. Karakunnel served as CMO and Senior Vice President at Tizona Therapeutics, where he led the development of the company’s biotherapeutics pipeline. Prior to Tizona, he held positions with Arcus...

Pierre Dodion, MD, Directeur Médical, prend sa retraiteInnate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui la nomination du Dr Joyson Karakunnel au poste de Vice-président exécutif et Directeur Médical. Pierre Dodion, Directeur Médical d’Innate Pharma depuis 2014, part à la retraite.Dr Karakunnel rejoint la Société avec une expérience substantielle en immuno-oncologie et en développement de médicaments. En tant que Directeur Médical, il sera responsable de l’avancement du portefeuille clinique d’Innate et dirigera une équipe globale centrée sur la stratégie clinique, la sécurité des patients, les affaires réglementaires et les affaires médicales.Dernièrement, Dr Karakunnel était Directeur Médical et Vice-président senior chez Tizona Therapeutics, où il a mené...

Borregaard’s operating revenues increased to NOK 1,358 million (NOK 1,340 million)¹ in the 2nd quarter of 2020. EBITDA² reached an all-time high of NOK 361 million (NOK 283 million). BioMaterials and Fine Chemicals had improved results, whereas BioSolutions had a result in line with the same period last year.BioSolutions had a significant reduction in raw material supply and hence lower sales volume, offset by an improved product mix and favourable currency effects. In BioMaterials, lower wood and energy costs, high production volume and positive currency effects more than compensated for a lower sales volume. For Fine Chemicals, sales of bioethanol to disinfectants was the main reason for the improved result. The total net currency impact on EBITDA was approximately NOK 30 million compared with the corresponding period in 2019.During...

F-Secure Corporation, Half Year Financial Report, 16 July 2020 at 08.00 EESTF-Secure Half Year Financial Report 1 January – 30 June 2020Improved profitability in challenging market environment Highlights of April-June (Q2)Revenue remained at previous year’s level, and was EUR 53.0 million (54.1m)Revenue from corporate security decreased by 6% to EUR 28.2 million (30.1m)Revenue from consumer security increased by 3% to EUR 24.8 million (24.0m)Adjusted EBITDA was EUR 10.2 million (4.8m), 19.3% of revenue (8.9%)EBIT was EUR 6.0 million (3.3m), 11.4% of revenue (6.1%)Earnings per share (EPS) was EUR 0.02 (EUR 0.02)Cash flow from operating activities before financial items and taxes was EUR 11.4 million (6.9m)F-Secure withdrew its financial outlook for 2020 in April due to COVID-19 related market uncertaintiesHighlights of January-June...

F-Secure Oyj, puolivuosikatsaus, 16.7.2020, klo 08.00F-Securen puolivuosikatsaus 1.1. – 30.6.2020Kannattavuus vahvistui haastavassa markkinaympäristössäKeskeiset tapahtumat huhti-kesäkuussa (Q2)Liikevaihto pysyi edellisen vuoden tasolla ja oli 53,0 miljoonaa euroa (54,1 milj. eur)Liikevaihto yritystietoturvasta laski 6% ja oli 28,2 miljoonaa euroa (30,1 milj.eur)Liikevaihto kuluttajatietoturvasta kasvoi 3%, ja oli 24,8 miljoonaa euroa (24,0 milj.eur)Oikaistu käyttökate oli 10,2 miljoonaa euroa (4,8 milj.eur) ja 19,3% liikevaihdosta (8,9%)Liikevoitto oli 6,0 miljoonaa euroa (3,3 milj.eur) ja 11,4% liikevaihdosta (6,1%)Osakekohtainen tulos oli 0,02 euroa (0,02)Liiketoiminnan rahavirta ennen rahoituseriä ja veroja oli 11,4 miljoonaa euroa (6,9 milj.eur)Huhtikuussa F-Secure perui vuodelle 2020 annetut taloudelliset näkymät COVID-19 -pandemian...

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) — Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock (the “Shares”), each at a price to the public of $16.00 per share. Gross proceeds to Atreca from the offering are expected to be $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  In addition, Atreca has granted the underwriters a 30-day option to purchase up to 1,171,875 additional shares of its Class A Common Stock at the public offering price,...

BASKING RIDGE, N.J., July 16, 2020 (GLOBE NEWSWIRE) — The 5G Future Forum, a group of global 5G leaders accelerating the delivery of Multi-access Edge Computing-enabled solutions around the world, will release its first technical specifications to its members in the third quarter of 2020 – a major step forward in enabling global interoperability for 5G and Multi-access Edge Computing (MEC) deployment to deliver efficient and innovative services to end customers.  There are two major sets of technical specifications:The “MEC Experience Management” technical specification defines a set of intent-based APIs for functional exposure of edge and workload discovery with potential expansion to include future MEC functions and capabilities which are driven by network intelligenceThe “MEC Deployment” technical specification defines the set...